Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: ABV-press 2014-11-01
Sarja:Onkourologiâ
Aiheet:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Linkit:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia